Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic

Patent metadata

Field	Value
Publication number	US-9492398-B2
Application number	US-201213985686-A
Country	US
Kind code	B2
Filing date	Feb 24, 2012
Priority date	Feb 25, 2011
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

A composition, an encapsulated composition and/or nanoparticles comprising at least one essential oil having a large spectrum antibacterial, antiparasitic, antifungal activity and/or a plant antipathogen, optionally at least one antibiotic and optionally a pharmaceutically acceptable carrier is disclosed. Methods for treating infectious diseases and especially bacterial, parasitic, fungal and/or plant infectious by using this composition, encapsulated composition and/or nanoparticles are also disclosed.

First claim

Having described the invention, the following is claimed:

1. A composition comprising at least one essential oil or essential oil extract having a broad spectrum antibacterial activity, antiparasitic activity, antifungal activity, undesirable vegetation activity, weed activity and/or plant antipathogenic activity, wherein:
a. said essential oil or essential oil extract is encapsulated within nanoparticles or lipidic nanocapsules obtained by a phase-inversion temperature method, whereby lipidic nanocapsules have an oily core of medium-chain triglycerides surrounded by a membrane made of lecithin and a PEGylated surfactant, and nanoparticles have a membrane made of lecithin and a PEGylated surfactant and no medium-chain triglycerides oily core, and
b. said essential oil or essential oil extract is selected from the group of: essential oil from oregano, essential oil or essential oil extract from thyme, essential oil or essential oil extract from cloves, essential oil or essential oil extract from savory, essential oil or essential oil extract from ravintsara, essential oil or essential oil extract from laurel leaves, essential oil or essential oil extract from scotch pine, essential oil or essential oil extract from eucalyptus, essential oil or essential oil extract from paper bark, essential oil or essential oil extract from cinnamon and mixtures thereof.

2. The composition according to claim 1 , further comprising at least one antibiotic that is either encapsulated within nanoparticles or lipidic nanocapsules along with the at least one essential oil or essential oil extract, or found in the composition in association with at least one essential oil or essential oil extract encapsulated within nanoparticles or lipidic nanocapsules, wherein said at least one antibiotic is selected from the group of a beta-lactamine antibiotic, amoxicilline, clavulanic acid, piperacilline which can be associated or not with tazobactam, cloxacillin, cefuroxime, cefotaxime or impenem, an aminoside antibiotic, gentamicin or amikacin, a fluroquinolone antibiotic, ciprofloxacin or ofloxacin, a fosfomycine antibiotic, a glycopeptide antibiotic, vancomycin or teicoplanin, a nitrofuran antibiotic, a rifamycin antibiotic, a macrolide antibiotic, josamycin or clarithromycin, a nitro-imidazole antibiotic, a sulfamide, a trimethoprim antibiotic, a synergistin antibiotic, their pharmaceutically acceptable salts and mixtures thereof.

3. The composition according to claim 1 , wherein at least one essential oil is selected from the group of: essential oil from oregano from Spain or Morocco or the Balkans, essential oil or essential oil extract from the leaves of cloves, essential oil or essential oil extract from green paper bark, essential oil or essential oil extract from red thyme, essential oil or essential oil extract from Chinese cinnamon and mixtures thereof.

4. The composition according to claim 1 , wherein the essential oils or essential oil extracts comprise or consist of:
about 5 to about 40% by weight, or about 20% to about 30% by weight, or about 25% by weight, of essential oil or essential oil extract from oregano; and/or
about 1% to about 25% by weight, or about 3% to about 14% by weight, or about 9% by weight, of essential oil or essential oil extract from thyme; and/or
about 1% to 75% by weight, or about 70% by weight, of essential oil or essential oil extract from cloves; and/or
about 1% to 20% by weight, or about 1% to about 12% by weight, or about 6% by weight, of essential oil or essential oil extract from savory; and/or
about 1% to 20% by weight, or about 4% to about 15% by weight, or about 9% by weight, of essential oil or essential oil extract from ravintsara; and/or
about 1% to 20% by weight, or about 4% to about 15% by weight, or about 9% by weight, of essential oil or essential oil extract from laurel leaves; and/or
about 1% to 20% by weight, or about 1% to about 12% by weight, or about 6% by weight, of essential oil or essential oil extract from scotch pine; and/or
about 1% to 20% by weight, or about 1% to about 12% by weight, or about 6% by weight, of essential oil or essential oil extract from paper bark; and/or
about 1% to 30% by weight, or about 1% to about 15% by weight, or about 15% by weight, of essential oil or essential oil extract from cinnamon.

5. The composition according to claim 1 , comprising about 15% by weight of an essential oil from oregano, about 70% by weight of an essential oil from clove and about 15% by weight of essential oil from cinnamon and optionally at least one antibiotic that is encapsulated or associated with the at least one essential oil or comprising of about 63.28% of an essential oil extract from clove or clove leaves, 11.86% of essential oil extract from cinnamon, 13.56% of an essential oil extract from cinnamon bark and 11.3% of an essential oil extract from oregano, cloves and/or cinnamon.

6. The composition according to claim 1 , comprising an essential oil from oregano from Morocco or the Balkans having about 33.20% or 70% of carvacrol (14.7 unit grams of carvacrol), an essential oil from clove leaves or cloves from Madagascar having 82.57% eugenol (70.6 unit grams of eugenol) and essential oil from cinnamon from China having 77.57% of trans cinnamaldehyde (14.7 unit grams of trans cinnamaldehyde).

7. The composition according to claim 1 , having four essential oil extracts, which are about 11.86% carvacrol extract (5.25 unit grams of carvacrol) from oregano, 63.28% eugenol (54.10 unit grams of eugenol) an essential oil extract from clove leaves or cloves from Madagascar, 13.56% of trans cinnamaldehyde extract (2.57 unit grams of trans cinnamaldehyde) an essential oil extract from cinnamon from China and 11.3% trans-β-caryophyllene (1.80 unit grams of trans-β-caryophyllene) from oregano, cloves and/or cinnamon.

8. The composition according to claim 1 , wherein the nanoparticle has a size of between 1 nm and 100 nm and wherein 100 μl to 500 μl of said essential oil(s) is encapsulated or the lipidic nanocapsule has a size of between 20 nm and 200 nm and wherein 100 μl to 500 μl of said essential oil(s) is encapsulated.

9. The composition according to claim 1 , wherein each of the at least one essential oil(s) or at least one essential oil extract present in said composition is encapsulated at a concentration ranging from 0.01% to 2% by weight, 0.05% to 0.5% by weight, 0.05% to 1% by weight, 0.5% to 80% by weight or 0.2% to 25% by weight.

10. The composition according to claim 1 , wherein the lipidic nanocapsule comprises a mixture of soybean lecithin at 69% of phosphatidylcholine, caprylic-capric acid triglycerides and a mixture of free polyethylene glycol 660 and polyethylene glycol 66-hydroxystearate.

11. The composition according to claim 1 , further comprising a pharmaceutically acceptable carrier that is saline or buffered saline, and/or the composition is further formulated to be administered as a medicament.

Assignees

• Rossines Elisabeth
• Joly-Guillou Marie Laure
• Saulnier Patrick
• Benoit Jean Pierre
• Eydo Pharma
• Inst Nat Sante Rech Med
• Université d'Angers

Inventors

• Rossines Elisabeth
• Joly-Guillou Marie Laure
• Saulnier Patrick
• Benoit Jean Pierre

Classifications

• A61K9/5146

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides · CPC title

• A61K9/51 Primary

  Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)} · CPC title

• A61K36/61

  Myrtaceae (Myrtle family), e.g. teatree or eucalyptus · CPC title

• A61K9/5123

  Organic compounds, e.g. fats, sugars · CPC title

• A61K31/733

  Fructosans, e.g. inulin · CPC title